Creso Pharma Ltd set to benefit as regulatory shifts on cannabis and broadened global footprint underpin growthPosted by On


In the quarter to December 2020, there were a number of significant shifts in the regulatory environment, which have the capacity to unlock a number of near-term and medium-term openings.

() (FRA:1X8), which saw rapid growth in its December quarter with a number of major milestones in the international markets, is set to benefit from the changing global attitudes to cannabis. 

In the quarter to December 2020, there were a number of significant shifts in the regulatory environment, which have the capacity to unlock a number of near-term and medium-term openings. 

The company is being positioned to capitalise on such opportunities as they develop. 

Quarter of rapid growth

Non-executive chairman Adam Blumenthal said: “The quarter was a period of rapid growth for the company.

“Creso achieved a number of major milestones in international markets, which were underpinned by pleasing regulatory shifts.

“Pleasingly, Creso continued to expand its global footprint. Through the company’s animal health business, we entered into the Latin American market and Mernova continued to gain traction in Canada, progressing agreements and purchase orders to unlock a number of new provinces.

“The company also furthered its presence in the Australian and New Zealand markets, securing an agreement with Martin & Pleasance to drive growth.

“Strong sales were achieved over…

Original Author Link click here to read complete story..

In the quarter to December 2020, there were a number of significant shifts in the regulatory environment, which have the capacity to unlock a number of near-term and medium-term openings.

() (FRA:1X8), which saw rapid growth in its December quarter with a number of major milestones in the international markets, is set to benefit from the changing global attitudes to cannabis. 

In the quarter to December 2020, there were a number of significant shifts in the regulatory environment, which have the capacity to unlock a number of near-term and medium-term openings. 

The company is being positioned to capitalise on such opportunities as they develop. 

Quarter of rapid growth

Non-executive chairman Adam Blumenthal said: “The quarter was a period of rapid growth for the company.

“Creso achieved a number of major milestones in international markets, which were underpinned by pleasing regulatory shifts.

“Pleasingly, Creso continued to expand its global footprint. Through the company’s animal health business, we entered into the Latin American market and Mernova continued to gain traction in Canada, progressing agreements and purchase orders to unlock a number of new provinces.

“The company also furthered its presence in the Australian and New Zealand markets, securing an agreement with Martin & Pleasance to drive growth.

“Strong sales were achieved over…



Source link

News

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.